Hdl Handle:
http://hdl.handle.net/10147/206383
Title:
Targeting regulatory T cells in cancer.
Authors:
Byrne, William L; Mills, Kingston H G; Lederer, James A; O'Sullivan, Gerald C
Affiliation:
Cork Cancer Research Centre, Mercy University Hospital and Leslie C. Quick Jnr., Laboratory, University College Cork, Cork, Ireland.
Citation:
Cancer Res. 2011 Nov 15;71(22):6915-20. Epub 2011 Nov 8.
Journal:
Cancer research
Issue Date:
31-Jan-2012
URI:
http://hdl.handle.net/10147/206383
DOI:
10.1158/0008-5472.CAN-11-1156
PubMed ID:
22068034
Abstract:
Infiltration of tumors by regulatory T cells confers growth and metastatic advantages by inhibiting antitumor immunity and by production of receptor activator of NF-kappaB (RANK) ligand, which may directly stimulate metastatic propagation of RANK-expressing cancer cells. Modulation of regulatory T cells can enhance the efficacy of cancer immunotherapy. Strategies include depletion, interference with function, inhibition of tumoral migration, and exploitation of T-cell plasticity. Problems with these strategies include a lack of specificity, resulting in depletion of antitumor effector T cells or global interruption of regulatory T cells, which may predispose to autoimmune diseases. Emerging technologies, such as RNA interference and tetramer-based targeting, may have the potential to improve selectivity and efficacy.
Language:
eng
MeSH:
CTLA-4 Antigen/antagonists & inhibitors; Forkhead Transcription Factors/antagonists & inhibitors; Humans; Lymphocyte Depletion; Neoplasms/*immunology/*therapy; T-Lymphocytes, Regulatory/*immunology
ISSN:
1538-7445 (Electronic); 0008-5472 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorByrne, William Len_GB
dc.contributor.authorMills, Kingston H Gen_GB
dc.contributor.authorLederer, James Aen_GB
dc.contributor.authorO'Sullivan, Gerald Cen_GB
dc.date.accessioned2012-01-31T16:38:08Z-
dc.date.available2012-01-31T16:38:08Z-
dc.date.issued2012-01-31T16:38:08Z-
dc.identifier.citationCancer Res. 2011 Nov 15;71(22):6915-20. Epub 2011 Nov 8.en_GB
dc.identifier.issn1538-7445 (Electronic)en_GB
dc.identifier.issn0008-5472 (Linking)en_GB
dc.identifier.pmid22068034en_GB
dc.identifier.doi10.1158/0008-5472.CAN-11-1156en_GB
dc.identifier.urihttp://hdl.handle.net/10147/206383-
dc.description.abstractInfiltration of tumors by regulatory T cells confers growth and metastatic advantages by inhibiting antitumor immunity and by production of receptor activator of NF-kappaB (RANK) ligand, which may directly stimulate metastatic propagation of RANK-expressing cancer cells. Modulation of regulatory T cells can enhance the efficacy of cancer immunotherapy. Strategies include depletion, interference with function, inhibition of tumoral migration, and exploitation of T-cell plasticity. Problems with these strategies include a lack of specificity, resulting in depletion of antitumor effector T cells or global interruption of regulatory T cells, which may predispose to autoimmune diseases. Emerging technologies, such as RNA interference and tetramer-based targeting, may have the potential to improve selectivity and efficacy.en_GB
dc.language.isoengen_GB
dc.subject.meshCTLA-4 Antigen/antagonists & inhibitorsen_GB
dc.subject.meshForkhead Transcription Factors/antagonists & inhibitorsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshLymphocyte Depletionen_GB
dc.subject.meshNeoplasms/*immunology/*therapyen_GB
dc.subject.meshT-Lymphocytes, Regulatory/*immunologyen_GB
dc.titleTargeting regulatory T cells in cancer.en_GB
dc.contributor.departmentCork Cancer Research Centre, Mercy University Hospital and Leslie C. Quick Jnr., Laboratory, University College Cork, Cork, Ireland.en_GB
dc.identifier.journalCancer researchen_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.